A5100436737- Cancer Genomics and Diagnostics
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Colorectal and Anal Carcinomas
- Melanoma and MAPK Pathways
- Colorectal Cancer Surgical Treatments
- Colorectal Cancer Screening and Detection
- Pancreatic and Hepatic Oncology Research
- Molecular Biology Techniques and Applications
- Genomics and Rare Diseases
- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Gastric Cancer Management and Outcomes
- Inflammatory Bowel Disease
- Genetic factors in colorectal cancer
- Cancer Cells and Metastasis
- Single-cell and spatial transcriptomics
- Prostate Cancer Treatment and Research
- Viral-associated cancers and disorders
- Gene expression and cancer classification
- Hepatocellular Carcinoma Treatment and Prognosis
- Nanoplatforms for cancer theranostics
- Chemokine receptors and signaling
- Actinomycetales infections and treatment
- Acute Lymphoblastic Leukemia research
Sir Run Run Shaw Hospital
2025
Zhejiang University
2025
Shanghai Jiao Tong University
2014-2024
Institute of Molecular Genetics
2023
Shanghai Ninth People's Hospital
2022
First Affiliated Hospital of Chengdu Medical College
2018-2022
Nantong University
2022
Group Sense (China)
2022
Yantaishan Hospital
2022
Shanghai Sixth People's Hospital
2022
Importance The clinical effects of risankizumab (a monoclonal antibody that selectively targets the p19 subunit IL-23) for treatment ulcerative colitis are unknown. Objective To evaluate efficacy and safety when administered as an induction a maintenance therapy patients with colitis. Design, Setting, Participants Two phase 3 randomized trials were conducted. trial was conducted at 261 centers (in 41 countries) enrolled 977 from November 5, 2020, to August 4, 2022 (final follow-up on May 16,...
Head and neck squamous cell carcinoma (HNSCC) is a common frequently lethal cancer with few therapeutic options. In particular, there are effective targeted therapies. Development of highly strategies tailored to patients HNSCC remains pressing challenge. To address this, we present pharmacogenomic study facilitate precision treatments for HNSCC. We established large collection 56 patient-derived cells (PDCs), which recapitulated the molecular features original tumors. Pharmacological...
Leveraging single-cell gene expression profiles can significantly enhance our understanding of diseases by associating single cells with traits such as disease subtypes, prognosis, and drug response. Although previous efforts have linked cell clusters groups these attributes, they primarily focused on changes in proportions while overlooking transcriptional at the level. To further unravel heterogeneity reveal nuanced behaviors cellular it is essential to assess associations individual...
Background: Although a number of monoimmunotherapies and targeted therapies are available to treat BRAF+ advanced melanoma, response rates remain relatively low in the range 22–53% with progression-free survival (PFS) 4.8–8.8 months. Recently, combination have improved about 66–69%, PFS 11.0–12.6 months overall (OS) 25.1–25.6 While immunotherapies 67 compared 19–29% monotherapies 11.7 4.4–5.8 monotherapies, OS benefit is yet be established phase 3 trials. As healthcare costs continue rise,...
The prevalence of lung cancer, a highly complex neoplasm, increases annually. Thus, cancer biobank, which stores tissue and blood matched according to standard methods, is needed advance research develop promising therapies.To accomplish this aim, we implemented standardized procedures for samples patient information acquired from consenting donors. banked includes blood, pleural effusions, surgical resection samples. An independent management system was used match collect data, including...
Abstract Background TP53 mutations are frequent in non‐small cell lung cancer (NSCLC). Different categories of may be associated with survival advanced NSCLC, but their effect on prognosis is diverse. To date, a comprehensive comparison the relationship between different classes alterations and NSCLC has rarely been performed. Moreover, prognostic significance novel approach called evolutionary action (EAp53) unclear. Methods A total 210 patients harboring mutation data were enrolled....
Breast cancer is a highly heterogeneous disease. Early-stage, non-metastatic breast considered curable after definitive treatment. Early detection of tumor recurrence and metastasis through sensitive biomarkers helpful for guiding clinical decision-making early intervention in second-line treatment, which could improve patient prognosis survival.In this real-world study, we retrospectively analyzed 82 patients with stages I to III who had been by molecular residual disease (MRD) assay. A...
Aim: We compared outcomes from a single-arm study of tisagenlecleucel with standard care (SOC) regimens in pediatric and young adult patients relapsed/refractory acute lymphoblastic leukemia (ALL). Methods: The analysis included one study, blinatumomab clofarabine monotherapy three studies combination two other salvage chemotherapy. Matching-adjusted indirect comparison analyses were conducted. Results: After adjusting for baseline characteristics, was associated significantly prolonged...
310 Background: FLC, a rare liver cancer of young adults, has no effective systemic therapies. Surgical resection is used extensively with non-curative intent. FLC associated DNAJB1- PRKACA chimeric transcript that produces fusion protein retained kinase activity and increased expression several oncogenic signaling pathways including, but not limited to, HER2 ( ERBB2). Methods: N (240 mg oral daily) was studied in pts the SUMMIT study (NCT01953926); later under compassionate use for N-based...
It is essential to analyze rare mutations in many fields of biomedical research. However, the detection usually failed due interference predominant wild-type DNA surrounded. Herein we describe a sensitive and facile method detecting point mutation on basis allele-specific amplification emulsion PCR. The identification selective are accomplished one-pot reaction. primers coupled magnetic beads allow exclusive enrichment mutant amplicons. productive bearing amplicons subsequently stained with...
Abstract Background: KRAS is frequently mutated in human cancers, including pancreatic (~90%), colorectal (~35%), and lung cancer (~25%). The KRASG12C mutation (single amino acid substitution of cysteine for glycine at position 12) accounts ~14% cancer, ~4% ~2% cancer. Currently, two covalent inhibitors, namely sotorasib (AMG-510) adagrasib (MRTX-849), have been approved as monotherapy to treat locally advanced or metastatic NSCLC with through accelerated approval process. Despite the...
8080 Background: EGFR T790M mutation occurs in around half of non-small cell lung cancer (NSCLC) patients with acquired EGFR-TKI (TKI) resistance, based on tumor tissue re-biopsies using an invasive clinical procedure. Here, we evaluated the feasibility detecting circulating DNA (ctDNA), serial plasma samples from NSCLC receiving TKI to further investigate its association outcome. Methods: Patients advanced or recurrent were enrolled consecutively and blood taken every 2 months, including...